Tag: Envision Pharma Group

• Alice will lead the organization’s IMC division made up of experts in medical strategy, medical communications, publications planning and delivery, patient engagement, and more to deliver smarter, faster outcomes for life sciences clients.

Envision Pharma Group (Envision) has appointed Alice Choi as President, Integrated Medical Capabilities and Solutions (IMC) and a member of its Executive Leadership Team. In her new role, Alice will lead the organization’s IMC division made up of experts in medical strategy, medical communications, publications planning and delivery, patient engagement, and more to deliver smarter, faster outcomes for life sciences clients.

“I am so pleased to welcome Alice to the Envision team and her invaluable experience as a global life sciences industry leader,” shares Howard Miller, CEO of Envision Pharma Group. “Alice brings a depth of strategic expertise, knowledge, and insight in the medical communications, scientific research, and publications field that will be instrumental in propelling our vision forward for our people and serving the needs of our clients.”

Alice joins Envision from IPG Health where she most recently served as EVP, Managing Director, Client Solutions, APAC. Prior to this, the bulk of her career was in IPG Health Medical Communications – latterly as Chief Operating Officer for the group and formerly, as Head of Complete Medical Communications. During her tenure, she played a pivotal role in establishing and fulfilling long-term business goals while focusing on building upon key client relationships to foster sustained business growth, development, and operational excellence across several global teams. 

Alice is committed to best practices and standards in medical communications, as demonstrated in her current role as Chair of the Healthcare Communications Association and through her success at IPG Health Medical Communications and former tenure as Chair of the International Society of Medical Publications Professionals (ISMPP).

Alice adds, “I have long admired the work done by Envision and am excited to be joining such a stellar team. Medical communications continue to move at a rapid pace, and I look forward to ensuring that we continue leading the field in terms of our people, our quality, and our innovative patient-centric services.”

About Envision Pharma Group
Founded in 2001, Envision Pharma Group is a leading global technology-enabled strategic solutions partner for the life sciences industry, working with over 200 pharma and biotech companies, including 19 of the top 20 pharmaceutical companies. Envision supports clients across the product life cycle through a comprehensive suite of services and industry-leading technology solutions that include artificial intelligence and natural language processing, commercialization and integrated strategic consulting, evidence-based scientific communications and engagement, HEOR/market access and data analytics, medical capabilities, and omnichannel solutions. Learn more at www.envisionpharmagroup.com.

CONTACTS
Colleen Carter
Associate Director, Communications, Office of CEO
colleen.carter@envisionpharma.com
1 (508) 505 8856

• The new board and leadership appointment aligns with the company’s commitment to advancing the industry through innovation and the expansion of AI across its solutions

Envision Pharma Group (Envision), a leading global technology-enabled strategic solutions partner for the life sciences industry, unveils its AI Innovation Board and announces the appointment of Dr. Loubna Bouarfa as AI thought leader and Chairwoman of the newly established board. This strategic move underscores Envision’s global commitment to harnessing the power of AI to shape the future of the life sciences industry.

Previously serving as the CEO and founder of OKRA.ai, which was acquired by Envision in February 2023, Dr. Bouarfa revolutionized healthcare by creating AI systems that support life sciences companies to better enable the drive of personalized medicine across the globe. In this new role, she will apply her deep expertise to intertwine AI with all the services that Envision offers.

“Loubna’s appointment and the establishment of the new AI Innovation Board marks a significant step toward aligning our innovation and technology efforts to drive our strategies for our internal team, business, and partners,” shares Howard Miller, CEO of Envision Pharma Group. “We are confident this strategic move will propel Envision to new heights.”

In her new role, Dr. Bouarfa will focus on advancing AI strategy and promoting its integration across all aspects of Envision. This appointment solidifies Envision’s dedication to leveraging AI to deliver innovative, faster outcomes for the life sciences industry. In addition, Dr. Bouarfa will lead the AI Innovation Board to define and develop Envision’s AI strategy across all technology platforms, solidify thought leadership as pioneers in AI, and pilot new innovative AI applications.

Having earned the Deloitte Fast 50 Women in Leadership Award and a place on Forbes’ 50 Top Women in Tech list, Dr. Bouarfa expressed her commitment to the role, saying, “I am excited to take on this new challenge and continue driving AI innovation at Envision. We are dedicated to leading the industry in this space and delivering innovative solutions that will transform the future of life sciences. Our success will not only bring commercial benefit to clients but lead to improved patient outcomes across the globe.”

About Envision Pharma Group
Founded in 2001, Envision Pharma Group is a leading global technology-enabled strategic solutions partner for the life sciences industry, working with over 200 pharma and biotech companies, including 19 of the top 20 pharmaceutical companies. Envision supports clients across the product life cycle through a comprehensive suite of services and industry-leading technology solutions that include artificial intelligence and natural language processing, commercialization and integrated strategic consulting, evidence-based scientific communications and engagement, HEOR/market access and data analytics, medical capabilities, and omnichannel solutions. Learn more at www.envisionpharmagroup.com.

Contact Information
Colleen Carter
Associate Director, Communications, Office of CEO
colleen.carter@envisionpharma.com
1 (508) 505 8856

OKRA.ai, an Envision Pharma Group (Envision) company, has appointed senior leader Dr. Yahya Anvar as Chief of AI Science & Insights to unleash the full potential of artificial intelligence (AI) and to further support the life sciences industry.

“I am excited about continuing the innovative collaboration between Envision and OKRA.ai along with Yahya as a senior leader as it further solidifies our Envision commitment to the expansion of OKRA.ai and leadership in the AI and technical space,” shares Meg Heim, CEO of Envision Pharma Group. “His leadership is critical to our vision to accelerate the delivery of our compelling combination of technology-enabled capabilities and solutions to clients as we continue to strengthen our offerings across the product life cycle, but more importantly to support patients in their journey to health and wellness.”

Anvar joined OKRA.ai in 2019, heading the Data Science team. During his tenure, he has led the development of AI solutions across OKRA.ai’s portfolio of products and services. Prior to joining the company, he served as the principal investigator of preclinical personalized medicine at Leiden University Medical Center. He has over 14 years of experience in the healthcare sector and is the author of over 30 peer-reviewed scientific articles. Anvar holds a PhD in Computational Biology from the faculty of Medicine at Leiden University, and an MSc in Bioinformatics and Artificial Intelligence from Brunel University.

Anvar shares, “It is an absolute privilege to be leading the AI insights and science at Envision and pushing the boundaries of what AI has to offer to better patients’ outcomes. Making an impact through solutions that provide actionable, explainable insights is what we thrive for. There is no better time for new beginnings than today, and I’m so excited to be working with the Envision team to transform the industry as we know it.”

Dr. Loubna Bouarfa, Head of AI & Innovative Platforms at Envision, shares, “It was a pleasure to work with Yahya; he has been an exceptional leader of the Data Science team at OKRA.ai. His role has now expanded to cover AI insights and scientific expertise across the entire Envision organization following our recent acquisition. I look forward to working with him in driving AI innovation and propelling Envision to new heights.”

About Envision Pharma Group
Founded in 2001, Envision Pharma Group is a leading global technology-enabled strategic solutions partner for the life sciences industry, working with over 200 pharma and biotech companies, including 18 of the top 20 pharmaceutical companies. Envision supports clients across the product life cycle through a comprehensive suite of services and industry-leading technology solutions that include artificial intelligence and natural language processing, commercialization and integrated strategic consulting, evidence-based scientific communications and engagement, HEOR/market access and data analytics, medical capabilities, and omnichannel solutions. Learn more at www.envisionpharmagroup.com.

Contact Information:
Colleen Carter
Associate Director, Communications, Office of CEO
colleen.carter@envisionpharma.com
1 (508) 505 8856

Envision Pharma Group (Envision) today announced the appointment of Dr. Deepti Sodhi Jaggi to the Envision Board of Directors.

“We are pleased to welcome Deepti to the Envision Board of Directors,” shares Meg Heim, CEO of Envision Pharma Group. “Deepti’s deep experience in the technology of Artificial Intelligence (AI) and digital therapeutics in the life sciences industry will be invaluable to our mission at Envision as we continue to accelerate our global business expansion and commitment to our clients, and most importantly, impacting patient lives in a positive manner.”

Dr. Jaggi’s career includes over 20 years of experience in driving innovation at the intersection of life sciences, healthcare, and technology. Her expertise is in transforming businesses through software, AI/ML, and advanced analytics. Most recently, she served as Chief Strategy & Commercial Officer at Better Therapeutics, a publicly held digital therapeutics company. Before that, she served as the Global Head of Patient Insights & Solutions at Astellas Pharmaceuticals with responsibility for the Americas, EMEA, China, and Japan.

Prior to that, Dr. Jaggi served as President & Chief Medical Officer at Clinakos Inc., a Silicon Valley company at the forefront of leveraging data and AI in healthcare and life sciences. She helped grow Clinakos from startup to revenue stage, serving multiple top pharmaceutical companies.

Dr. Jaggi’s previous experience includes positions of increasing responsibility and leadership at Johnson & Johnson, Genentech, Oracle, and Kaiser Permanente. She has also served as a consultant to TPG Capital and is a member of the Board of Directors for Technology Credit Union in the San Francisco Bay Area.

“I am thrilled to join the Envision Board at such an exciting time for our industry. I look forward to working with an immensely talented team to accelerate innovation in life sciences through technology and scientific solutions to positively impact patient lives,” says Dr. Jaggi.

Dr. Jaggi’s educational background includes a PharmD from the University of Southern California and an MBA from Stanford Graduate School of Business.

About Envision Pharma Group
Founded in 2001, Envision Pharma Group is a leading global technology-enabled strategic solutions partner for the life sciences industry, working with over 200 pharma and biotech companies, including 18 of the top 20 pharmaceutical companies. Envision supports clients across the product life cycle through a comprehensive suite of services and industry-leading technology solutions that include artificial intelligence and natural language processing, commercialization and integrated strategic consulting, evidence-based scientific communications and engagement, HEOR/market access and data analytics, medical capabilities, and omnichannel solutions. Learn more at www.envisionpharmagroup.com.

Contact Information
Colleen Carter
Associate Director, Communications, Office of the CEO
colleen.carter@envisionpharma.com
1 (508) 505 8856

SOURCE: Envision Pharma Group

Envision Pharma Group (Envision) has appointed Dr. Jennifer Costello, PharmD, BCPS, CMPP, to the role of Chief Medical Officer. Jennifer will be responsible for progressing work across all sectors of Envision’s business, including Technology, Medical, Commercial, Public Affairs, and Value & Access and Data Analytics.

Meg Heim, CEO of Envision Pharma Group, adds, “I am so excited to welcome Jennifer to the Envision team as Chief Medical Officer. Jennifer’s deep expertise in science and commercialization in the life sciences industry, in addition to her extensive pharmaceutical understanding and experience will further support the acceleration of our business expansion, mission, and commitment to our vision as a technology-enabled partner to the life sciences industry.”

Jennifer is an accomplished pharmaceutical and healthcare leader with over 20 years of experience across the healthcare sector. She brings to this role extensive cardiovascular, medical, and patient care-related focused expertise, with a successful track record of leading high-performing cross-matrix teams with global impact.

Prior to joining Envision, Jennifer held multiple leadership roles in global medical affairs and publications, US HEOR publications, and global scientific content. She developed a reputation for leading successful partnerships with cross-functional colleagues, advocacy partners, and academic groups that resulted in building innovative programs that foster healthcare transformation.

Jennifer joins Envision from Bristol Myers Squibb, where she most recently led cardiovascular (CV) patient advocacy across its CV portfolio (early phase assets to marketed products). She drove the development and execution of global and US strategies for a successful launch of a first-in-class CV asset, working across early asset development, commercial, and medical affairs teams. For her work in this space, she was awarded the coveted “Innovation Award” from BMS.

Before joining the pharmaceutical industry, her 16 years of experience as a practicing clinical pharmacist was within the academic medical-teaching hospital. Jennifer served in numerous roles as a pediatric critical care specialist, adult ambulatory clinical care specialist, hospital administrator, and as a Director of Clinical Pharmacy Services. Under a collaborative practice agreement, she also led outpatient care optimization, directly co-managing heart failure, antithrombotic, and diabetic patients.

Jennifer received her PharmD from Northeastern University, completed her ASHP PGY-1 residency at the University of Arizona/University Medical Center, and received her board certification as a pharmacotherapy specialist from the American College of Clinical Pharmacy. She served in adjunct teaching positions with Rutgers University and the University of Florida. She has authored over 50 publications and posters and served as a pharmacy national thought leader within the heart failure, antithrombotic, and diabetes management space.

Jennifer adds, “I am delighted and humbled to join the Envision team during this transformative time. I am looking forward to meeting and working with our Envision family, customers, and partners. This is an exciting period for our industry at large, and I am privileged to build upon our company vision, award-winning technology, and innovation as medical affairs and global healthcare communication leaders.”

About Envision Pharma Group
Founded in 2001, Envision Pharma Group is a leading global technology-enabled strategic solutions partner for the life sciences industry, working with over 200 pharma and biotech companies, including 18 of the top 20 pharmaceutical companies. Envision supports clients across the product life cycle through a comprehensive suite of services and industry-leading technology solutions that include artificial intelligence and natural language processing, commercialization and integrated strategic consulting, evidence-based scientific communications and engagement, HEOR/market access and data analytics, medical capabilities, and omnichannel solutions. Learn more at www.envisionpharmagroup.com.

Contact Information
Colleen Carter
Associate Director, Communications, Office of the CEO
colleen.carter@envisionpharma.com
1 (508) 505 8856

SOURCE: Envision Pharma Group

Envision Pharma Group (Envision) has appointed Mike Glover to Senior Vice President, Payer and HTA Solutions. Mike will be responsible for leading and developing Envision’s distinctive market access and HTA strategies for early-stage and late-stage businesses, combining customer insights, vision, and creativity. Mike’s key focus areas will be transformations in patient access, global pricing strategies, real-world evidence, and improving patient outcomes.

Meg Heim, CEO of Envision Pharma Group, shares, “I am excited to welcome Mike to the team at Envision as Senior Vice President, Payer and HTA solutions. As we continue to accelerate Envision’s business expansion, mission, and commitment to our clients’ needs. Mike’s extensive experience in developing and executing cutting-edge access, policy, and pricing strategies while executing fully integrated market access programs will be critical in partnering with our clients to execute upon their goals, improve performance, and meet their unique business needs with the support of our technology platforms.”

Prior to joining Envision, Mike served as Vice President, Head of Global Access and Pricing Strategy for GlaxoSmithKline. Before that, he held various leadership positions of increasing responsibilities at GSK, Sanofi, and Bristol Myers Squibb. He brings with him a diverse background across multiple geographies, functions, and therapeutic areas. His global commercial leadership experiences spanning oncology, cardiovascular, diabetes, and virology from asset development to in-market delivery will be a valuable asset to Envision.

Mike adds, “The energy and passion of the Envision team shines through in every interaction I’ve had. It was this passion and desire to be the very best at what they do that made this an easy decision for me to join Envision. Our industry is facing a changing and challenging environment and Envision is building an organization that will not just deliver, but will become a true partner for our customers adding real value across the life cycle of a brand. I am delighted to be joining them at this important time in our industry’s future.”

About Envision Pharma Group
Founded in 2001, Envision Pharma Group is a leading global technology-enabled strategic solutions partner for the life sciences industry, working with over 200 pharma and biotech companies, including 18 of the top 20 pharmaceutical companies. Envision supports clients across the product life cycle through a comprehensive suite of services and industry-leading technology solutions that include artificial intelligence and natural language processing, commercialization and integrated strategic consulting, evidence-based scientific communications and engagement, HEOR/market access and data analytics, medical capabilities, and omnichannel solutions. Learn more at www.envisionpharmagroup.com.

Contact Information:
Colleen Carter
Associate Director, Communications, Office of the CEO
colleen.carter@envisionpharma.com
1 (508) 505 8856

SOURCE: Envision Pharma Group